In recent years, the clinical installation of immune checkpoint inhibitors (ICIs) has proven to be an exceptionally valuable addition to
oncological therapy, illustrating superior short- and long-term efficacy in challenging-to-treat malignancies and taking on an increasing
role across the majority of disease sites.